BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38644364)

  • 1. Tumor growth-arrest effect of tetrahydroquinazoline-derivative human topoisomerase II-alpha inhibitor in HPV-negative head and neck squamous cell carcinoma.
    Sarogni P; Brindani N; Zamborlin A; Gonnelli A; Menicagli M; Mapanao AK; Munafò F; De Vivo M; Voliani V
    Sci Rep; 2024 Apr; 14(1):9150. PubMed ID: 38644364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting topoisomerase II with trypthantrin derivatives: Discovery of 7-((2-(dimethylamino)ethyl)amino)indolo[2,1-b]quinazoline-6,12-dione as an antiproliferative agent and to treat cancer.
    Catanzaro E; Betari N; Arencibia JM; Montanari S; Sissi C; De Simone A; Vassura I; Santini A; Andrisano V; Tumiatti V; De Vivo M; Krysko DV; Rocchi MBL; Fimognari C; Milelli A
    Eur J Med Chem; 2020 Sep; 202():112504. PubMed ID: 32712536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Topoisomerase II Activity in NSCLC with 9-Aminoacridine Derivatives.
    Ferguson DM; Jacobson BA; Jay-Dixon J; Patel MR; Kratzke RA; Raza A
    Anticancer Res; 2015 Oct; 35(10):5211-7. PubMed ID: 26408679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel, Potent, and Druglike Tetrahydroquinazoline Inhibitor That Is Highly Selective for Human Topoisomerase II α over β.
    Ortega JA; Arencibia JM; Minniti E; Byl JAW; Franco-Ulloa S; Borgogno M; Genna V; Summa M; Bertozzi SM; Bertorelli R; Armirotti A; Minarini A; Sissi C; Osheroff N; De Vivo M
    J Med Chem; 2020 Nov; 63(21):12873-12886. PubMed ID: 33079544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of 1,2-diphenylethene derivatives as human DNA topoisomerase II catalytic inhibitors and antitumor agents.
    Xu G; Li Z; Ding Y; Shen Y
    Eur J Med Chem; 2022 Dec; 243():114706. PubMed ID: 36063665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topoisomerase II Inhibitors and Poisons, and the Influence of Cell Cycle Checkpoints.
    D Arcy N; Gabrielli B
    Curr Med Chem; 2017; 24(15):1504-1519. PubMed ID: 27919216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, Synthesis, Dynamic Docking, Biochemical Characterization, and
    Arencibia JM; Brindani N; Franco-Ulloa S; Nigro M; Kuriappan JA; Ottonello G; Bertozzi SM; Summa M; Girotto S; Bertorelli R; Armirotti A; De Vivo M
    J Med Chem; 2020 Apr; 63(7):3508-3521. PubMed ID: 32196342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticancer activity of dihydropyrazolo[1,5-c]quinazolines against rat C6 glioma cells via inhibition of topoisomerase II.
    Kaur G; Cholia RP; Joshi G; Amrutkar SM; Kalra S; Mantha AK; Banerjee UC; Kumar R
    Arch Pharm (Weinheim); 2018 Jun; 351(6):e1800023. PubMed ID: 29737542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.
    Järvinen TA; Tanner M; Rantanen V; Bärlund M; Borg A; Grénman S; Isola J
    Am J Pathol; 2000 Mar; 156(3):839-47. PubMed ID: 10702400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple Topoisomerase I (TopoI), Topoisomerase II (TopoII) and Tyrosyl-DNA Phosphodiesterase (TDP) inhibitors in the development of anticancer drugs.
    Baglini E; Salerno S; Barresi E; Robello M; Da Settimo F; Taliani S; Marini AM
    Eur J Pharm Sci; 2021 Jan; 156():105594. PubMed ID: 33059042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors.
    Fillmore CM; Xu C; Desai PT; Berry JM; Rowbotham SP; Lin YJ; Zhang H; Marquez VE; Hammerman PS; Wong KK; Kim CF
    Nature; 2015 Apr; 520(7546):239-42. PubMed ID: 25629630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacophore Hybridization To Discover Novel Topoisomerase II Poisons with Promising Antiproliferative Activity.
    Ortega JA; Riccardi L; Minniti E; Borgogno M; Arencibia JM; Greco ML; Minarini A; Sissi C; De Vivo M
    J Med Chem; 2018 Feb; 61(3):1375-1379. PubMed ID: 29077404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Search for human DNA topoisomerase II poisons in the group of 2,5-disubstituted-1,3,4-thiadiazoles.
    Plech T; Kaproń B; Paneth A; Wujec M; Czarnomysy R; Bielawska A; Bielawski K; Trotsko N; Kuśmierz E; Paneth P
    J Enzyme Inhib Med Chem; 2015 Dec; 30(6):1021-6. PubMed ID: 25792499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor regulates topoisomerase II activity and drug sensitivity in human KB cells.
    Allen GC; Lubas S; Wax MK; Devore RF
    Otolaryngol Head Neck Surg; 1996 Jun; 114(6):785-92. PubMed ID: 8643303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine.
    Walsby EJ; Coles SJ; Knapper S; Burnett AK
    Haematologica; 2011 Mar; 96(3):393-9. PubMed ID: 21134979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets.
    Skok Ž; Zidar N; Kikelj D; Ilaš J
    J Med Chem; 2020 Feb; 63(3):884-904. PubMed ID: 31592646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insight into Mechanism of Action of Anticancer Benzazoles.
    Ozturk O; Aki-Yalcin E; Yalcin I; Grifitth R
    Curr Top Med Chem; 2020; 20(23):2056-2069. PubMed ID: 32814529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel epoxypropoxy flavonoid derivative and topoisomerase II inhibitor, MHY336, induces apoptosis in prostate cancer cells.
    Patra N; De U; Kang JA; Kim JM; Ahn MY; Lee J; Jung JH; Chung HY; Moon HR; Kim HS
    Eur J Pharmacol; 2011 May; 658(2-3):98-107. PubMed ID: 21376033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
    Koole K; Brunen D; van Kempen PM; Noorlag R; de Bree R; Lieftink C; van Es RJ; Bernards R; Willems SM
    Clin Cancer Res; 2016 Aug; 22(15):3884-93. PubMed ID: 26936917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
    Morgan SE; Cadena RS; Raimondi SC; Beck WT
    Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.